Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | ALPL | P05186 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353593 | 0.91 | ALPL (0.71) | NPC1RAB9AALDH1A1ALPLMAPT | |
| SCHEMBL2368455 | 0.89 | ALPL (0.68) | NPC1RAB9AALDH1A1ALPLMAPT | |
| SCHEMBL12243303 | 0.88 | ALPL (0.68) | NPC1RAB9AALDH1A1ALPLMAPT | |
| SCHEMBL2349458 | 0.88 | ALPL (0.67) | NPC1RAB9AALPLMAPTMAPK1 | |
| SCHEMBL7329944 | 0.88 | ALPL (0.67) | NPC1RAB9AALPLMAPTMAPK1 | |
| SCHEMBL14985491 | 0.83 | GAA (0.63) | NPC1RAB9AALDH1A1ALPLMAPT | |
| SCHEMBL26094639 | 0.82 | MAP2K4 (0.56) | NPC1RAB9AALPLMAPTMAPK1 | |
| SCHEMBL17279929 | 0.81 | PRKD1 (0.54) | NPC1RAB9AALPLMAPTMAPK1 | |
| SCHEMBL26915302 | 0.80 | MAPT (0.50) | NPC1RAB9AALPLMAPTMAPK1 | |
| SCHEMBL14926635 | 0.80 | MAPT (0.68) | NPC1RAB9AALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | NPC1 506/4885RAB9A 2480/4885ALDH1A1 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.